|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS, SUCH AS ASPIRIN, MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
MODERATE DOSES OF ASPIRIN MAY INCREASE THE EFFECTIVENESS OF ORAL HYPOGLYCEMIC DRUGS, LEADING TO HYPOGLYCEMIA
|
CO-ADMINISTRATION CAN LEAD TO HIGH SERUM CONCENTRATION OF ACETAZOLAMIDE DUE TO COMPITITION AT RENAL TUBULES FOR SECRETION AND TOXICITY LEADING TO ANOREXIA,TACHYCARDIA,LETHARGYNESS,COMA & DEATH
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THE EFFECTIVENESS OF DIURETICS IN PATIENTS WITH UNDERLYING RENAL OR CARDIOVASCULAR DISEASE MAY BE DIMINISHED BY CO-ADMINISTRATON OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
PATIENTS ON ANTICOAGULATION THERAPY ARE AT RISK FOR BLEEDING
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND VALPROIC ACID LEADING TO AN INCREASE IN SERUM VALPROIC ACID LEVELS
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
ASPIRIN CAN INCREASE THE ANTICOAGULANT ACTIVITYOF HEPARIN, INCREASING BLEEDING RISK
|
SALICYLIC ACID CAN INHIBIT RENAL CLEARANCE OF METHOTREXATE, LEADING TO BONE MARROW TOXICITY, ESPECIALLY IN ELDERLY OR RENAL IMPAIRED PT.
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
DIPYRIDAMOLE MAY COUNTERACT THE ANTICHOLINESTERASE EFFECT OF CHOLINESTERASE INHIBITORS, THEREBY POTENTIALLY AGGRAVATING MYASTHENIA GRAVIS
|
SALICYLIC ACID CAN DISPLACE PROTEIN-BOUND PHENYTOIN LEADING TO A DECREASE IN THE TOTAL CONCENTRATION OF PHENYTOIN
|
SALICYLATES ANTAGONIZE THE URICOSURIC ACTION OF URICOSURIC AGENTS, SUCH AS PROBENECID, SULPHINPYRAZONE
|
SALICYLATES ANTAGONIZE THE URICOSURIC ACTION OF URICOSURIC AGENTS, SUCH AS PROBENECID, SULPHINPYRAZONE
|
SALICYLATES ANTAGONIZE THE URICOSURIC ACTION OF URICOSURIC AGENTS, SUCH AS PROBENECID, SULPHINPYRAZONE
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
ASPIRIN CAN DISPLACE WARFARIN FROM PROTEIN BINDING SITES, LEADING TO A PROLONGATION OF BOTH THE PROTHROMBIN TIME AND THE BLEEDING TIME
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|